Work

Comparative effectiveness of non-cisplatin (cis)-based first-line (1L) regimens in patients with metastatic urothelial carcinoma (mUC): Veterans Affairs control cohorts vs. IMvigor210.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.6_suppl.496

Authors: Nancy S. Vander Velde, Annie Guerin, Raluca Ionescu-Ittu, Sherry Shi, Eric Wu, Shih-Wen Lin, Ling-I Hsu, Kai-Uwe Saum, Sabine De Ducla, Jingjing Wang, Shi Li, Christina Louise Derleth, Shuqian Liu, Lizheng Shi, John Leppert

Institutions: Southeast Louisiana Veterans Health Care System, Analysis Group (United States), Genentech, Roche Pharma AG (Germany), F. Hoffmann-La Roche AG, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Tulane University, VA Palo Alto Health Care System

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2793748304

Cites:

Cited by: 1

Related to: 10